Salesforce Slump Deepens as AI Monetization Doubts Eclipse Strong Q1 Metrics

What happened

Salesforce stock has fallen over 50% from its peak, as market sentiment turns sharply against the company amid 'SaaSpocalypse' fears and persistent doubts about its AI-driven growth strategy. The selloff persists despite strong Q1 FY27 results that showed 14% cRPO growth, $33.6B in current backlog, and Agentforce ARR reaching $1.2B, because investors question whether these metrics translate into durable organic revenue acceleration. The underlying business remains fundamentally sound with $67.9B in total remaining performance obligations and robust free cash flow of $6.6B, but the quality of growth is clouded by acquisition contributions, shifting pricing models, and a debt-financed $25B buyback that has reduced balance sheet flexibility. The market now requires clear evidence that Agentforce adoption is converting into sustained subscription growth, not just usage metrics or bundled ARR, before re-rating the stock. Thus, the next two quarters will be decisive as management's claim of second-half organic acceleration must be validated by cRPO trends and cleaner disclosure.

Implication

Investors should remain on the sidelines until Q2 and Q3 FY27 results provide clearer proof that Agentforce is driving organic reacceleration. While the current price of $163 already discounts considerable skepticism, it does not fully price in risks of seat compression from AI substitution or further guidance disappointment. The debt-funded $25B buyback increases financial risk, leaving less room for error if growth disappoints. The base case target of $170 offers limited upside, while a bear case to $145 is plausible if cRPO slips below 12%. A re-assessment window of 3-6 months is appropriate, with a trim level above $195 and an attractive entry at $150.

Thesis delta

The narrative has shifted from early AI adoption optimism to a rigorous 'show me' phase where investors demand tangible evidence of organic growth acceleration. The earlier bull case premised on Agentforce-driven reacceleration now hinges on whether cRPO holds above 14% and subscription growth materially improves by Q3. This shift increases uncertainty and delays any re-rating until proof emerges, justifying a neutral to cautious stance.